Pharmacokinetics, Pharmacodynamics, and Safety of Single-Dose Rivaroxaban in Chronic Hemodialysis.

CONCLUSIONS: Changes in PK and PD parameters in chronic dialysis patients were generally comparable to changes observed previously in patients with moderate-to-severe renal impairment who were not undergoing dialysis, and support use of a 15-mg dose in this patient population.
PMID: 27100875 [PubMed - as supplied by publisher]

Source: American Journal of Nephrology - April 21, 2016 Category: Urology & Nephrology Authors: Dias C, Moore KT, Murphy J, Ariyawansa J, Smith W, Mills RM, Weir MR Tags: Am J Nephrol Source Type: research